As of 10:13 on March 28, 2025, the SSE Science and Technology Innovation Board 100 Index (000698) rose 0.61%, the constituent stocks Mabwell Biotech (688062) rose 13.94%, Shenzhou Cell (688520) rose 6.51%, Remegen Biotech (688331) rose 6.31%, GoodWe (688390) rose 5.10%, and Zhixiang Jintai (688443) rose 5.02%. The STAR 100 Index ETF (588030) rose 0.50%, hitting three consecutive gains. The latest price is reported at 1 yuan, and the intraday turnover has reached 71.6511 million yuan, temporarily ranking 1/10 of comparable ETFs, with a turnover rate of 1.12%.

On the news side, the 2024 annual report performance briefing of the Science and Technology Innovation Board is ready to go. From April 28th to May 9th, seven "Subdivided Industry Chain Dialogue Days" activities will be carried out in turn, including artificial intelligence, robotics, low-altitude economy, semiconductor equipment, intelligent consumption, innovative drugs, and new energy, so as to facilitate investors to horizontally compare the development trends of various industries and the company's business advantages, and quickly grasp the core points in the development tasks in 2025.

Industry analysts pointed out that the performance briefing is not only a stage for enterprises to showcase their innovative achievements, but also a key channel for the market to re-anchor the value of technology assets.

The STAR 100 Index ETF closely tracks the SSE STAR Market 100 Index, which selects 100 securities with medium market capitalization and good liquidity from the SSE STAR Market as a sample. The SSE STAR Market 100 Index and the SSE STAR Market 50 Component Index together constitute the SSE STAR Market Scale Index Series, which reflects the overall performance of securities of listed companies with different market capitalizations in the SSE STAR Market.

In terms of scale, the scale of the STAR 100 Index ETF has increased by 922 million yuan in the past one year, achieving significant growth.

The data shows that leveraged funds continue to be deployed. The latest financing purchase amount of the Science and Technology Innovation 100 Index ETF reached 18.6396 million yuan, and the latest financing balance reached 318 million yuan.

In terms of absolute return, as of March 27, 2025, since its inception, the STAR 100 Index ETF has the highest monthly return of 27.67%, the longest consecutive month of 3 months, the longest consecutive increase of 37.87%, and the average return of the rising month of 8.75%.

In terms of excess returns, as of March 27, 2025, the annualized return of the STAR 100 Index ETF over the benchmark in the past 1 year was 0.64%.

In terms of drawdown, as of March 27, 2025, the STAR 100 Index ETF has the largest drawdown of 7.83% this year, 0.20% relative to the benchmark.

In terms of fees, the STAR 100 Index ETF has a management fee of 0.15% and a custody fee of 0.05%, which is the lowest among comparable funds.

In terms of tracking accuracy, as of March 27, 2025, the tracking error of the STAR 100 Index ETF in the past 1 month is 0.012%, which is the highest tracking accuracy among comparable funds.

According to the data, as of February 28, 2025, the top ten weighted stocks of the SSE Science and Technology Innovation Board 100 Index (000698) are Smartway (688213), BeiGene (688235), Hengxuan Technology (688608), Ruichuang Micro-Nano (688002), Zhongke Feitest (688361), Yuntian Lifei (688343), Allist (688578), Guodun Quantum (688027), Huahong Company (688347), Green harmonic (688017), the top ten weighted stocks accounted for 24.45% of the total.

STAR 100 Index ETF (588030), OTC Connect (Bosera SSE STAR Market 100 ETF Connect A: 019857; Bosera SSE STAR Market 100 ETF Connect C:019858).